IDAHLIA RICHARDSON: Open Payments
NPI 1295198596 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$913 in 19 payments from 9 companies in 2025. Trend: 2023 $81 · 2024 $806 · 2025 $913
Food & beverage: $718Education: $195
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $375 |
| Janssen Biotech, Inc. | 2 | $133 |
| SANOFI-AVENTIS U.S. LLC | 1 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $64 |
| Syndax Pharmaceuticals, Inc. | 2 | $64 |
| JAZZ PHARMACEUTICALS INC. | 1 | $60 |
| Incyte Corporation | 2 | $57 |
| Merck Sharp & Dohme LLC | 1 | $35 |
| Gamida Cell Inc. | 1 | $24 |
Products named: Cresemba, DARZALEX, REZUROCK, LIVTENCITY, DEFITELIO, PREVYMIS, Xospata, NIKTIMVO.
Industry payments across TX — which companies pay providers there.
